TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03907657
Drug: Perflutren lipid microsphere
Normalized name: perflutren lipid microspheres
DrugBank: Perflutren (DB00556)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
Study: NCT01265537
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx:~0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4
Study: NCT01265537
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx~0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.
Study: NCT00720421
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam 1 mg oral 2 tablets
Study: NCT00720421
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam Placebo oral 2 tablets
Study: NCT04277637
Drug: Sonrotoclax
Normalized name: Sonrotoclax
DrugBank: Sonrotoclax (DB18753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablets administered once daily at a dose as specified in the treatment arm
Study: NCT04277637
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 320 mg daily administered as two 80-mg capsules twice a day (160 mg twice a day) or as four 80-mg capsules once a day (320 mg once a day)
Study: NCT04277637
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given as an intravenous infusion administered per label.
Study: NCT03907657
Drug: Sulfur hexafluoride lipid microspheres
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Lumason will be used as a secondary contrast agent only if Definity(perflutren) is unavailable.This drug will be administered using the dosing range and administration type within the Lumason prescribing information. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
Study: NCT00215280
Drug: ivermectin and albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03005665
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02446405
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00741338
Drug: Cyclosporine A (CsA)
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally three times daily.
Study: NCT03536611
Drug: dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dabigatran etexilate 110 mg bid + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by dabigatran 110mg bid + clopidogrel 75mg/d for at least 5 months
Study: NCT03536611
Drug: warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: warfarin (according to clinical routine monitoring of INR, maintain the therapeutic range at 2.0-3.0) + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by warfarin + clopidogrel 75mg/d for at least 5 months
Study: NCT02255968
Drug: EDP-788
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-788 Capsules. All interventions are given as multiple doses.
Study: NCT04245085
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in both treatment arms will receive atezolizumab at a fixed dose of 1200 mg i.v. on day one of every 3-week (3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.~Treatment beyond RECIST-defined progression will be allowed if patient is continuing to derive clinical benefit.
Study: NCT04245085
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients in both treatment arms will receive bevacizumab at a dose of 15 mg/kg i.v. on day one of every 3-week (+/- 3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.
Study: NCT04245085
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in treatment Arm A will receive carboplatin, AUC5 every 3 weeks for 4-6 cycles.
Study: NCT04245085
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients in treatment Arm A will receive paclitaxel, 175-200 mg/m2 (at the investigators' discretion), every 3 weeks for 4-6 cycles.
Study: NCT04245085
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients in treatment Arm B will receive Pemetrexed, 500 mg/m2 every 3 weeks until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.
Study: NCT01181570
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients receive adalimumab 80 mg followed by 40 mg at week 1 and 40 mg every other week (EOW) thereafter.
Study: NCT01666665
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
Study: NCT01666665
Drug: Sugar pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill up to 3 times per day for 12 months
Study: NCT02166658
Drug: Cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel 25 mg/m2 i.v. infusion (infusion time about 1h) on D1 of each 21-day cycle. Continuation of treatment until progression of brain metastases or unacceptable toxicity.
Study: NCT04327011
Drug: Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toca FC is an extended-release formulation of flucytosine.
Study: NCT00659243
Drug: rhBSSL
Normalized name: rhBSSL
DrugBank: Bucelipase alfa (DB16664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 g/L rhBSSL added to pasteurized breast milk; one week treatment
Study: NCT01586507
Drug: ULTRAM ER
Normalized name: Ultram ER
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
Study: NCT01586507
Drug: ULTRAM ER
Normalized name: Ultram ER
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
Study: NCT00442962
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600-mg tablet taken orally daily
Study: NCT00442962
Drug: Emtricitabine/Tenofovir disoproxil fumarate
Normalized name: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200-mg emtricitabine/300-mg tenofovir disoproxil fumarate tablet taken orally once daily
Study: NCT01493869
Drug: cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 25-mg strength capsules (75-mg dose) administered as a single oral dose on Day 1 of study participation
Study: NCT02228850
Drug: Alprostadil
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00533286
Drug: benzodiacepine
Normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam (2 x 5 mg/ die)
Study: NCT00742963
Drug: TH-302
Normalized name: TH-9402 free base
DrugBank: TH-9402 free base (DB17148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Dose escalation dose levels:~Dose level -1 (if needed): 180 mg/m2 Starting dose: 240 mg/m2
Study: NCT03126435
Drug: EndoTAG-1
Normalized name: Endostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice weekly
Study: NCT03126435
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: once weekly
Study: NCT02289703
Drug: Rivaroxaban 15 mg
Normalized name: rivaroxaban 15 MG
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single oral dose of rivaroxaban 15-mg tablet on Day 1 of each of the treatment periods.
Study: NCT00237978
Drug: Adapalen
Normalized name: Adapalene
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00697151
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin once a day, titrated to obtain an INR of 1.4 to 2.8; placebo aspirin once a day
Study: NCT00697151
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg once a day; placebo warfarin once a day
Study: NCT03901092
Drug: flortaucipir F 18
Normalized name: Flortaucipir F 18
DrugBank: Flortaucipir F-18 (DB14914)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No study drug will be administered.
Study: NCT03383978
Drug: Ezabenlimab
Normalized name: Ezabenlimab
DrugBank: Ezabenlimab (DB17483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of Ezabenlimab 240mg q 3 weeks
Study: NCT01794247
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01794247
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02253004
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral administration of active or placebo one week apart
Study: NCT00511732
Drug: Technosphere Insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Technosphere Insulin Inhalation Powder
Study: NCT00327756
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03500380
Drug: RC48-ADC
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RC48-ADC 2.0 mg/kg IV every 14 days
Study: NCT03500380
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib 1250 mg orally once daily during each 21-day cycle.
Study: NCT01404676
Drug: Add Vildagliptin
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Adding Vildagliptin 50 mg bid to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
Study: NCT01404676
Drug: Add Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adding Glimepiride 2mg to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
Study: NCT00866944
Drug: Adecatumumab
Normalized name: Adecatumumab
DrugBank: Adecatumumab (DB05006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adecatumumab,6-9mg/kg, every 14 days, 24 cycles
Study: NCT00866944
Drug: Adecatumumab and FOLFOX
Normalized name: Adecatumumab
DrugBank: Adecatumumab (DB05006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles
Study: NCT00430066
Drug: Imatinib Mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 400 mg/die for 6 months
Study: NCT00978614
Drug: Neramexane
Normalized name: Neramexane
DrugBank: Neramexane (DB04926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form:~25 mg immediate release \[IR\] tablets (=15.9 mg neramexane free base)~37.5 mg IR tablets (=23.9 mg neramexane free base)
Study: NCT02934464
Drug: RAMUCIRUMAB
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02934464
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel
Study: NCT01563497
Drug: PF-05089771
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dispersion TS formulation- fasted
Study: NCT01563497
Drug: PF-05089771
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets TS formulation- fasted
Study: NCT01563497
Drug: PF-05089771
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets TS formulation- fed
Study: NCT00940316
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally 150mg daily
Study: NCT00940316
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously 120mg/m2 for 6/6 genotype and 60mg/m2 for 6/7 genotype
Study: NCT00600587
Drug: neoadjuvant erlotinib therapy
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg erlotinib taken once daily and continued uninterrupted for 42 days before evaluation/thoracotomy/radiotherapy.
Study: NCT00600587
Drug: neoadjuvant gemcitabine/carboplatin therapy
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 cycles of neoadjuvant gemcitabine(1250mg/m2,d1,d8)/carboplatin(AUC=5,day1) chemotherapy before evaluation/thoracotomy/radiotherapy.
Study: NCT04940637
Drug: niraparib and dostarlimab
Normalized name: Dostarlimab
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: niraparib 300 mg/die and dostarlimab 500 mg day 1 Q3 weeks for the first 4 cycles followed by 1000 mg day 1 Q6 weeks
Study: NCT04535687
Drug: Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzoparib
Study: NCT00098774
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 g/sq m IV infusion over 2 hours q 12 hrs x 8 doses Days 1-4 of Cycle 6
Study: NCT00098774
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/kg IV infusion over 12 hrs q 12 hrs x 8 doses Days 1-4 of Cycle 6
Study: NCT00098774
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg/sq m PO Days 7-11 Cycles 1-5.
Study: NCT01426074
Drug: Bevacizumab 5 mg/kg
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenously every two weeks
Study: NCT02836548
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vorinostat 360 milligram once daily
Study: NCT00314210
Drug: Quetiapine SR
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00102622
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg/m\^2 intravenous (IV) every 7 days +/- 2 days for a total of 6 treatments.
Study: NCT03222856
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MK3475 (pembrolizumab) will be supplied directly as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution.
Study: NCT03222856
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin will be supplied as a clear and colourless aqueous solution for injection provided in glass vials containing 2 ml. Each 2 ml vial contains eribulin mesylate equivalent to 0.88 mg eribulin.
Study: NCT00780702
Drug: Airipiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants receive aripiprazole (orally, up to 15 mg/day) plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
Study: NCT02006732
Drug: olodaterol
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fixed dose combination
Study: NCT02006732
Drug: tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fixed dose combination
Study: NCT00668122
Drug: Cipro XR (Ciprofloxacin, BAYQ3939)
Normalized name: ciprofloxacin Extended Release Oral Tablet [Cipro]
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin XR 1000 mg orally once a day
Study: NCT00668122
Drug: Cipro IR (Ciprofloxacin, BAYQ3939)
Normalized name: ciprofloxacin Injection [Cipro]
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin IR 500 mg orally twice a day
Study: NCT00006123
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006123
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006123
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006123
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02388724
Drug: Vonoprazan
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan tablets
Study: NCT02388724
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole capsules
Study: NCT02388724
Drug: Vonoprazan Placebo
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan placebo-matching tablets
Study: NCT02388724
Drug: Lansoprazole Placebo
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole placebo-matching capsules
Study: NCT00803439
Drug: Clobetasol Propionate 0.05% Foam-Reference Product
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Small amount applied and evaluated over the course of two days
Study: NCT00803439
Drug: Clobetasol Propionate 0.05% Foam-Test product
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Small amount applied and evaluated over the course of two days
Study: NCT03899246
Drug: Eight Percent Topical Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description
Study: NCT00299130
Drug: Folate
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A stable dose, ≥ 5 mg/week given as either a single dose or as a divided weekly dose, orally.
Study: NCT00299130
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT00299130
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion
Study: NCT00437697
Drug: dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03142191
Drug: CC-90001
Normalized name: CC-90001
DrugBank: CC-90001 (DB18445)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-90001 is a potent, selective inhibitor of JNK.
Study: NCT01755091
Drug: Dronabinol
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01755091
Drug: Placebo (for Dronabinol)
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00527410
Drug: RTA 744
Normalized name: RTA 744
DrugBank: RTA 744 (DB05920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solution of RTA 744 is packaged in 5 ml vials - 1 mg/ ml. The drug is mixed in D10W and infused over 2 hours on three consecutive days.
Study: NCT00775619
Drug: Carvedilol 12.5 mg tablets
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bioequivalence Carvedilol 12.5 mg tablets fed conditions
Study: NCT02308124
Drug: Midodrine
Normalized name: Midodrine
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02308124
Drug: Pyridostigmine Bromide
Normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no